证券代码：688073 证券简称：毕得医药 公告编号：2026-006 上海毕得医药科技股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 本次会议是否有被否决议案：无 一、会议召开和出席情况 （一）股东会召开的时间：2026年2月9日 （二）股东会召开的地点：上海市杨浦区翔殷路999号3幢6层会议室 （三）出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及其持有表决权数量的情 况： 二、议案审议情况 （一）非累积投票议案 1、议案名称：关于修订《董事、高级管理人员薪酬管理制度》的议案 审议结果：通过 表决情况： ■ （四）表决方式是否符合《公司法》及公司章程的规定，股东会主持情况等。 本次股东会由董事长戴岚女士主持，会议采用现场投票与网络投票相结合的表决方式进行表决。本次会 议的召集、召开符合《公司法》《公司章程》《公司股东会议事规则》等法律、法规和规范性文件的规 定。 （五）公司董事和董事会秘书的列席情况 1、公司在任董事7人，出席7人； 2、 ...

北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于上海毕得医药科技股份有限公司 2026 年第一次临时股东会的 法律意见书 国枫律股字[2026]A0051 号 致：上海毕得医药科技股份有限公司（贵公司） 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出席并见 证贵公司 2026 年第一次临时股东会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称 "《股东会规则》"）、《律师事务所从事证券法律业务管理办法》（以下简称"《证 券法律业务管理办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简 称"《证券法律业务执业规则》"）等相关法律、行政法规、规章、规范性文件及《上 海毕得医药科技股份有限公司章程》（以下简称"《公司章程》"）的规定，就本次会 议的召集与召开程序、召集人资格、出席会议人员资格、会议表决程序及表决结果等事 ...

证券代码：688073 证券简称：毕得医药 公告编号：2026-006 上海毕得医药科技股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2026 年 2 月 9 日 （二） 股东会召开的地点：上海市杨浦区翔殷路 999 号 3 幢 6 层会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 56 | | --- | --- | | 普通股股东人数 | 56 | | 2、出席会议的股东所持有的表决权数量 | 38,128,636 | | 普通股股东所持有表决权数量 | 38,128,636 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 44.2570 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 44.2570 | （四） 表 ...

2月9日，毕得医药大宗交易成交8.34万股，成交额475.2万元，占当日总成交额的7.65%，成交价57元， 较市场收盘价61.36元折价7.11%。 | 交易日期 | 证券調核 | 证券代码 | | | 成交价(元) 成交金额(万元) 成交量(*) 买入营业部 | | 类出营业部 | 是否为专场 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2026-02-09 | 毕得医药 | 688073 | 57 | 270 | 4.74 | 是有限公司送路 | ្នកនិងចំនួន | | Ka | | 2026-02-09 | 毕得医药 | 688073 | 57 | 205.2 | 3.6 | 日本公司 2017年 | ទឹកនឹងដងដើ | | Ka | ...

Group 1 - The core transaction of Bid Pharma on February 5 involved 70,400 shares traded at a price of 57 yuan, totaling 4,007,400 yuan, which accounted for 6.43% of the total trading volume for that day [1] - The transaction price represented a discount of 7.44% compared to the market closing price of 61.58 yuan [1] - The trading was executed by Guangfa Securities and UBS, indicating active participation from major brokerage firms [2]

Market Performance - The medical services sector increased by 2.52% on February 3, with Norsig leading the gains [1] - The Shanghai Composite Index closed at 4067.74, up by 1.29%, while the Shenzhen Component Index closed at 14127.1, up by 2.19% [1] Top Gainers in Medical Services - Norsig (301333) closed at 78.98, up by 8.76% with a trading volume of 43,200 shares and a transaction value of 332 million [1] - Yinos (688710) closed at 61.07, up by 7.52% with a trading volume of 17,400 shares and a transaction value of 10.4 million [1] - Dean Diagnostics (300244) closed at 24.73, up by 6.69% with a trading volume of 447,200 shares and a transaction value of 1.084 billion [1] Market Capital Flow - The medical services sector saw a net inflow of 506 million from institutional investors, while retail investors experienced a net outflow of 4.12 billion [2][3] - The top stocks with significant institutional inflows included Tiger Medical (300347) with 103 million and Meinian Health (002044) with 86 million [3] Stock Performance Overview - The stock performance of various companies in the medical services sector showed a mix of gains and losses, with notable declines in stocks like Haocen Medical (002622) down by 1.97% [2] - The trading volume and transaction values varied significantly across different companies, indicating diverse investor interest [2]

证券研究报告 | 行业简评报告 2026 年 02 月 03 日 布局消费反转！ 大消费组二月消费金股 研究部/消费品 % 1m 6m 12m 绝对表现 4.3 4.6 25.0 相对表现 3.1 -8.7 1.7 资料来源：公司数据、招商证券 -10 0 10 20 30 Feb/25 May/25 Sep/25 Jan/26 (%) 消费品 沪深300 相关报告 1、《招商证券 1 月港股消费观察： 外卖反垄断如何影响港股消费股前 景？》2026-01-27 2、《大消费组一月消费金股—双节 消费亮点前瞻》2026-01-06 ❑ 轻纺 杨蕊菁：看好家居板块修复以及倍加洁益生菌业务发展 风险提示：消费下行风险，消费复苏疲软风险、宏观经济变动风险等。 推荐（维持） 行业规模 | | | 占比% | | --- | --- | --- | | 股票家数（只） | 1216 | 23.5 | | 总市值（十亿元） | 17628.3 | 15.6 | | 流通市值（十亿元） | 16321.4 | 15.9 | 行业指数 3、《招商证券 12 月港股消费观察— 1-2 月流动性改善后港股消费买什 么？》2025 ...

Investment Rating - The investment rating for the healthcare industry is "Positive" and maintained [14] Core Insights - The funding levels for Chinese innovative pharmaceutical companies are increasing, leading to a gradual improvement in the research and development (R&D) investment sentiment within the industry. This is expected to usher in a new cycle of prosperity for the innovative drug industry chain [5][12] - The trend of external business development (BD) is likely to benefit the domestic early-stage research industry significantly, as new business models allow early-stage projects to become tradable and monetizable assets, enhancing R&D investment returns [13] Summary by Sections Innovative Chain Development Review - Before 2020, multiple factors converged to initiate a significant rise in China's innovative drug sector, leading to the rapid development of the innovative chain, including CXO and life sciences services [10][30] - From 2020 to the first half of 2022, the global public health crisis accelerated capital inflow into the biopharmaceutical sector, resulting in high demand and a leap in the innovative chain segment, which also triggered a wave of IPOs and substantial supply-side expansion [10][39] - The second half of 2022 to 2024 saw a transition from a heated to a cooling phase, with a significant shift in supply-demand dynamics leading to industry internal competition and pressure on revenues and profit margins [10][54][57] Improvement in R&D Investment Sentiment - Starting from 2025, the R&D investment sentiment in China's innovative drug sector is expected to improve, with companies experiencing increased funding levels. The total amount raised through IPOs and additional offerings in 2025 is projected to reach 201.5 billion yuan, a 145% year-on-year increase [11][62] - The potential milestone payments from external BD are expected to reach 880.5 billion yuan in 2025, marking a 185.9% year-on-year increase, indicating a robust funding environment for innovative drug companies [11] Benefits to Early-stage Research Industry - The new external BD business model enhances the R&D investment return rates for Chinese innovative drug companies, thereby increasing their willingness to invest in R&D [11][13] - The early-stage research industry, including drug discovery CROs and clinical trial services, is expected to benefit significantly from the external BD trend, with leading companies in these segments poised for rapid growth [13]

Summary of Key Points Core Viewpoint - The A-share market saw a total of 41 stocks engaged in block trading today, with a total transaction value of 897 million yuan, indicating active trading activity in the market [1] Trading Activity - The top three stocks by transaction value were Zijin Mining at 264 million yuan, Longxin Technology at 55.37 million yuan, and Wanshili at 47.83 million yuan [1] - Among the stocks, 9 were traded at par, 1 at a premium, and 31 at a discount; ST Mingcheng was the only stock that traded at a premium with a premium rate of 0.58% [1] - The stocks with the highest discount rates included Tianhong Lithium at 28.75%, Tianyin Electric at 26.57%, and Bid Medical at 17.64% [1] Institutional Trading - The ranking of institutional buy amounts was led by Longxin Technology at 55.37 million yuan, followed by Zotye Auto at 19.99 million yuan, and Wankai New Materials at 19.99 million yuan [1] - Other notable institutional buys included Laplace at 17.61 million yuan, Yiwei Lithium Energy at 15.32 million yuan, and Chenfeng Technology at 10.30 million yuan [1] - The top institutional sell amounts were led by Yiwei Lithium Energy at 15.32 million yuan and Wolong Nuclear Materials at 4.44 million yuan [1]

| Public Prices were 1 kid LPS L | | | | | | | --- | --- | --- | --- | --- | --- | | 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额(万元) 成交量( *) 买入营业部 | | 奥出营业部 是否为专场 | | 026-02-02 | 毕得医药 | 688073 | 48 206.88 4.31 | 公司可能提高品 | Ki 發動產品 | 2月2日，毕得医药大宗交易成交4.31万股，成交额206.88万元，占当日总成交额的2.04%，成交价48 元，较市场收盘价58.28元折价17.64%。 ...